Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methsuximide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.70 |
| ▸ | BACE1 | P56817 | 6/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methsuximide SCHEMBL34852 | 1.00 | CYP19A1 (0.70) | CYP19A1BACE1BACE2ALDH1A1REN | |
| Methsuximide SCHEMBL28248761 | 0.87 | CYP19A1 (0.55) | CYP19A1BACE1BACE2ALDH1A1REN | |
| Methsuximide SCHEMBL28142879 | 0.83 | KMT2A (0.67) | CYP19A1BACE1TSHRMEN1KMT2A | |
| Methetoin SCHEMBL5886219 | 0.81 | CYP19A1 (0.49) | CYP19A1BACE1ALDH1A1TSHRCYP2C19 | |
| SCHEMBL14037658 | 0.81 | CYP19A1 (0.47) | CYP19A1BACE1BACE2TSHRCYP2C19 | |
| SCHEMBL29116647 | 0.80 | CYP19A1 (0.50) | CYP19A1BACE1BACE2ALDH1A1REN | |
| Methsuximide SCHEMBL28872768 | 0.78 | CYP19A1 (0.46) | CYP19A1BACE1BACE2ALDH1A1REN | |
| SCHEMBL13684394 | 0.77 | CYP19A1 (0.44) | CYP19A1BACE1ALDH1A1MEN1KMT2A | |
| SCHEMBL11930003 | 0.77 | CYP19A1 (0.44) | CYP19A1BACE1ALDH1A1CYP2C19MEN1 | |
| SCHEMBL24126788 | 0.75 | ELANE (0.56) | CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6558 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076971-A1 | METHODS OF TREATING EPILEPSY AND REDUCING THE INCIDENCE OF SEIZURES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-03-19 | — | — | US | claimed |
| US-12498384-B2 | Biomarkers and methods for evaluation and treatment of epileptic vs non-epileptic seizures / no seizures / psychogenic non-epileptic seizures | COGNIZANCE BIOMARKERS, INC. (US) | 2025-12-16 | — | — | US | claimed |
| US-20250367203-A1 | METHODS OF TREATING EPILEPSY AND REDUCING THE INCIDENCE OF SEIZURES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-12-04 | — | — | US | claimed |
| EP-4536219-A1 | METHOD OF TREATING EXPRESSIVE LANGUAGE DEFICIT IN AUTISTIC HUMANS | Niesen, Charles, E. (US) | 2025-04-16 | — | — | EP | claimed |
| EP-3518975-B1 | FORMULATION COMPRISING FENFLURAMINE AND CANNABIDIOL AND ITS USE IN THE TREATMENT OF SEIZURES | ZOGENIX INTERNATIONAL LTD (GB) | 2025-04-09 | — | — | EP | claimed |
| WO-2024263598-A1 | COMPOSITIONS & METHOD OF TREATING EPILEPSY BY SELECTIVE SEQUESTRATION OF SOLUBLE TNF | INMUNE BIO INC. (US) | 2024-12-26 | — | — | WO | claimed |
| EP-4465051-A2 | BIOMARKERS AND METHODS FOR EVALUATION AND TREATMENT OF EPILEPTIC VS NON-EPILEPTIC SEIZURES / NO SEIZURES / PSYCHOGENIC NON-EPILEPTIC SEIZURES | Cognizance Biomarkers, Inc. (US) | 2024-11-20 | — | — | EP | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240269066-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING XEROPHTHALMIA | PRECVISION BIOTECHNOLOGIES LTD. (CN) | 2024-08-15 | — | — | US | claimed |
| US-20240238247-A1 | METHOD OF TREATING EXPRESSIVE LANGUAGE DEFICIT IN AUTISTIC HUMANS | AMS Therapeutics, LLC (US) | 2024-07-18 | — | — | US | claimed |
| US-5662926-A | SOLVENT FREE | BERTEK, INC. (US) | 1997-09-02 | — | — | US | claimed |
| EP-0758228-A1 | EFFECTIVE DOSAGE FORM FOR ANTIEPILEPTIC DRUGS | ALZA CORPORATION (US) | 1997-02-19 | — | — | EP | claimed |
| EP-0746342-A1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES LTD. (US) | 1996-12-11 | — | — | EP | claimed |
| US-5518730-A | Biodegradable controlled release flash flow melt-spun delivery system | FUISZ TECHNOLOGIES LTD. (US) | 1996-05-21 | — | — | US | claimed |
| EP-0746342-A4 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES LTD (US) | 1996-01-11 | — | — | EP | claimed |
| WO-1995029665-A1 | EFFECTIVE DOSAGE FORM FOR ANTIEPILEPTIC DRUGS | ALZA CORPORATION (US) | 1995-11-09 | — | — | WO | claimed |
| WO-1993024154-A1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES, LTD. (US) | 1993-12-09 | — | — | WO | claimed |
| EP-0563507-A1 | Transdermal patch incorporating a polymer film incorporated with an active agent | MLI ACQUISITION CORP. II (US) | 1993-10-06 | — | — | EP | claimed |
| US-5192550-A | Dosage form for treating central nervous system disorders | ALZA CORPORATION (US) | 1993-03-09 | — | — | US | claimed |
| US-4160818-A | Fluorimetric immunoassay for diphenylhydantoin | TECHNICON INSTRUMENTS CORPORATION (US) | 1979-07-10 | — | — | US | claimed |